Keyword Analysis & Research: genelux corporation
Keyword Research: People who searched genelux corporation also searched
Search Results related to genelux corporation on Search Engine
-
Genelux Corporation | Redefining Immuno-Oncology
https://genelux.com/
WEBGenelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational therapies at the appropriate time and in a clinically appropriate manner for patients.
DA: 68 PA: 76 MOZ Rank: 27
-
Genelux Corporation (GNLX) - Yahoo Finance
https://finance.yahoo.com/quote/GNLX
WEBFind the latest Genelux Corporation (GNLX) stock quote, history, news and other vital information to help you with your stock trading and investing.
DA: 89 PA: 24 MOZ Rank: 80
-
Genelux Corporation - Wikipedia
https://en.m.wikipedia.org/wiki/Genelux_Corporation
WEBU.S. Products. Olvi-Vec. Website. www.genelux.com. Genelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
DA: 91 PA: 16 MOZ Rank: 100
-
Genelux Corporation | Genelux Corporation Reports Fourth …
https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-reports-fourth-quarter-and-full-year-2023
WEBApr 1, 2024 · Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update. April 1, 2024. PDF Version. – Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 –. …
DA: 90 PA: 58 MOZ Rank: 76
-
Genelux Corporation | Pipeline
https://genelux.com/overview/
WEBOverview. We are dedicated to developing a pipeline of next-generation immunotherapies for patients suffering with aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here and clinicaltrials.gov.
DA: 45 PA: 51 MOZ Rank: 34
-
Genelux Corporation | Investors
https://investors.genelux.com/
WEBNov 14, 2023 · Company Profile. The Genelux Difference. Genelux is a Phase 3 biopharmaceutical company developing powerful therapeutics for patients suffering from difficult-to-treat cancers. The Company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm ...
DA: 64 PA: 9 MOZ Rank: 35
-
Genelux Corporation | Technology
https://genelux.com/our-science/
WEBGenelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational therapies at the appropriate time and in a clinically appropriate manner for patients.
DA: 71 PA: 22 MOZ Rank: 96
-
Genelux Corporation | Genelux Corporation Receives FDA Fast …
https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-receives-fda-fast-track-designation-olvi-vec
WEBNov 27, 2023 · WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of ...
DA: 74 PA: 66 MOZ Rank: 25
-
Genelux Corporation Receives FDA Fast Track Designation for
https://www.globenewswire.com/news-release/2023/11/27/2786017/0/en/Genelux-Corporation-Receives-FDA-Fast-Track-Designation-for-Olvi-Vec-in-Platinum-Resistant-Refractory-Ovarian-Cancer.html
WEBNov 27, 2023 · WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...
DA: 54 PA: 26 MOZ Rank: 46
-
Genelux Corporation | Our Program
https://genelux.com/our-program/
WEBGenelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational therapies at the appropriate time and in a clinically appropriate manner for patients.
DA: 14 PA: 30 MOZ Rank: 64